Oncotelic Launches AI-Powered GMP Manufacturing Platform

Oncotelic Therapeutics (OTCQB: OTLC) has unveiled a groundbreaking AI-powered good manufacturing practices (GMP) manufacturing services platform at the 2026 BIO International Convention in San Diego. This innovative platform integrates the company’s proprietary PDAOAI technology with advanced robotics from its strategic partner, TechForce Robotics. Designed to revolutionize pharmaceutical and biotechnology manufacturing, the platform supports electronic batch records, GMP workflow digitization, quality and compliance functions, and real-time process monitoring. By leveraging AI-driven workflows and intelligent automation, Oncotelic aims to help companies modernize their manufacturing operations, reduce errors, and accelerate time-to-market for critical therapeutics.

In addition to the platform launch, Oncotelic highlighted progress with its Deciparticle nanomedicine platform, particularly SAPU003, a clinical-stage intravenous everolimus program currently under evaluation in a Phase 1b study. The company also emphasized its broader pipeline, which targets high-unmet-need cancers and rare pediatric indications. Under the leadership of CEO Dr. Vuong Trieu, who holds 75 U.S. patents and has filed over 500 patent applications, Oncotelic continues to advance its drug development efforts. Notably, the company owns 45% of GMP Bio, a joint venture further complementing its oncology and rare disease portfolio.

The collaboration with TechForce Robotics is central to the platform’s success, combining Oncotelic’s AI expertise with purpose-built automation solutions for pharmaceutical manufacturing. This partnership aligns with the growing industry trend toward digital transformation and Industry 4.0 in life sciences. For more details, the full press release is available at https://ibn.fm/upnBW. Oncotelic’s newsroom provides ongoing updates at https://ibn.fm/OTLC.